Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended Union Pacific (UNP), supported by BofA's Buy rating and price target increase to $262, while expressing concerns about BioMarin Pharmaceutical (BMRN) and its orphan drug model. He favored ARS Pharmaceuticals (SPRY), citing better-than-expected sales, but voiced disappointment in GitLab (GTLB) due to expensive enterprise software, aligning with GitLab's lower-than-expected Q2 sales guidance; NuScale Power (SMR) gained favor, with Cramer suggesting a buy after a potential offering, following a UBS analyst's Neutral rating and price target increase to $34.

Analysis

The "Mad Money Lightning Round" highlighted varied investor sentiment across several equities, underscored by specific analyst actions and company fundamentals. Union Pacific (UNP) received a positive endorsement, reinforced by a BofA Securities price target increase from $256 to $262, despite a minor 0.4% share price decline to $225.72. Conversely, GitLab (GTLB) faced significant headwinds, with its shares plummeting 10.6% to $43.37 after issuing Q2 revenue guidance with a midpoint ($226 million to $227 million) below the $227.16 million analyst estimate, aligning with Cramer's concerns over the high valuation of enterprise software; its Q2 adjusted EPS guidance of 16 to 17 cents, however, bracketed the 16 cent estimate. BioMarin Pharmaceutical (BMRN), whose shares fell 0.6% to $57.16, is navigating skepticism regarding its orphan drug model alongside its recent agreement on May 16 to acquire Inozyme in an all-cash transaction for approximately $270 million. ARS Pharmaceuticals (SPRY), despite a 2.4% fall to $14.34, was lauded for its technology and better-than-expected Q1 sales reported on May 14. NuScale Power (SMR) experienced a substantial 20.4% surge to $41.60, notably exceeding UBS's recently upgraded price target of $34 (from $17), with Cramer suggesting a cautious entry contingent on a future stock offering, referencing the Oklo (OKLO) situation.

Key Decisions for Investors

• Investors might view Union Pacific favorably, considering the positive analyst outlook and strong endorsement, potentially using minor price dips as accumulation opportunities.
• Exercise significant caution with GitLab due to its weaker-than-expected Q2 revenue guidance and substantial share price decline, reflecting concerns about its valuation and the broader enterprise software sector.
• Closely monitor BioMarin Pharmaceutical's integration of Inozyme and its strategic implications, weighed against expressed concerns about the viability of its core orphan drug model.
• ARS Pharmaceuticals could be considered a speculative investment based on its promising technology and recent strong sales performance, though its recent stock price volatility warrants attention.
• For NuScale Power, it may be prudent to await a potential stock offering to establish a position, given the stock's recent sharp appreciation significantly above its upgraded analyst price target.